AI-generated summary
The authors ran a double-blind study of 20 people with Alzheimer type dementia, giving 3 mg melatonin or a placebo for four weeks and tracking sleep and activity with actigraphy. They report that melatonin was associated with longer nighttime sleep and less nighttime activity, and with better ADAS cognition and non-cognition scores, though daytime measures did not differ. The study was small, and the authors describe their own findings as tentative, with melatonin possibly having a weaker effect on circadian rhythm than bright light therapy.
- Participants
- 20
- Who or what was studied
- People with Alzheimer type dementia, mean age 79.2 years, 17 females and 3 males; 18 had usable actigraphy data (8 placebo, 10 melatonin).
- Limits stated in the abstract
- Small sample of 20 participants with only 18 yielding usable actigraphy data, and the authors describe the melatonin effect as possibly less strong than bright light therapy.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on jstage.jst.go.jp.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Dementia, Bright light therapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.